Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data.
- Author:
Sun Hyong YOU
1
;
Byung Joo CHAE
;
Yong Hwa EOM
;
Tae Kyung YOO
;
Yong seok KIM
;
Jeong Soo KIM
;
Woo Chan PARK
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; ErbB-2 receptor; Estrogen receptors; Hormones; Trastuzumab
- MeSH: Breast Neoplasms*; Breast*; Estrogens; Follow-Up Studies; Humans; Multivariate Analysis; Phenobarbital; Prognosis; Receptor, Epidermal Growth Factor; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Retrospective Studies; Seoul; Trastuzumab; Treatment Outcome
- From:Journal of Breast Cancer 2018;21(4):415-424
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Triple-positive breast cancer is defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity. Several systemic breast cancer therapies target hormonal and HER2 responsiveness. We compared clinical outcomes of triple-positive disease with those of HER2-enriched and luminal HER2-negative disease and investigated the clinical efficacy of anti-HER2 therapy for triple-positive disease. METHODS: We retrospectively compared overall and recurrence-free survival among cases included in the Korean Breast Cancer Society (KBCS) and Seoul St. Mary's Hospital breast cancer registries and the therapeutic efficacy of trastuzumab for triple-positive and HER2-enriched cases. RESULTS: KBCS registry data (2006–2010; median follow-up, 76 months) indicated that patients with triple-positive breast cancer had intermediate survival between those with luminal A and HER2-enriched subtypes (p < 0.001). Trastuzumab did not improve overall survival among patients with triple-positive breast cancer (p=0.899) in contrast to the HER2-enriched subtype (p=0.018). Seoul St. Mary's Hospital registry data indicated similar recurrence-free survival outcomes (p < 0.001) and a lack of improvement with trastuzumab among patients with triple-positive breast cancer (median follow-up, 33 months; p=0.800). Multivariate analysis revealed that patients with triple-positive breast cancer had better overall survival than those with HER2-enriched disease and similar survival as those with the luminal A subtype (triple-positive: hazard ratio, 1.258, p=0.118; HER2-enriched: hazard ratio, 2.377, p < 0.001). CONCLUSION: Our findings showed that anti-HER2 therapy was less beneficial for treatment of triple-positive breast cancer than for HER2-enriched subtypes of breast cancer, and the triple-positive subtype had a distinct prognosis.
